CTNNB1 and hepatocellular carcinoma: The NFE2L2/KEAP1 pathway activation with CTNNB1 mutations with loss of genomic stability and telomerase-reverse-transcriptase (TERT) promoter was reported for aggressive HB with HCC features [4].